Posttraumatic Stress Disorders in Police, Correctional Service Officers, and 911 Operators

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

64 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-30

Study Completion Date

2023-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Police officers, correctional service officers, and 911-operators are at increased risk for suffering from trauma-related disorders due to their direct and indirect exposure to life-threatening events, such as shootings, violent assaults, or car accidents, among others. Typical treatments for post-traumatic stress disorders include psychotherapy and pharmacological therapies (i.e., antidepressants). Although these interventions are effective for many sufferers, they all have limitations. Thus, the investigators propose to explore the usefulness of a new therapeutic technique, reconsolidation blockade, which involves reactivating the trauma memory while under the influence of propranolol. Objectives and hypotheses: To explore the efficacy and cost-effectiveness of reconsolidation blockade therapy as an adjunct treatment for trauma- and stressor-related disorders as defined in the Diagnostic and Statistical Manual Mental Disorders-5. The investigators hypothesize that, compared to the control group, 5 weekly trauma-memory reactivations under propranolol treatment will confer a significant reduction in trauma-related symptoms and significantly more health-related economic benefits. Stress symptoms and health-related costs will be assessed at 7, 26 and 52 weeks after study inclusion. In this study, the investigators will also explore the effects of reconsolidation blockade with propranolol on various neuropsychological functions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparing Standard vs. Modified Reconsolidation Blockade for the Treatment of Psychological Trauma

NCT04982211

Trauma and Stressor Related Disorders Post Traumatic Stress Disorder Acute Stress Disorder +1 more

UNKNOWN PHASE2

Effect of Propranolol on Preventing Posttraumatic Stress Disorder

NCT00158262

Post-Traumatic Stress Disorder

COMPLETED PHASE4

Effectiveness of Propranolol For Treating People With Post-Traumatic Stress Disorder

NCT00648375

Post-Traumatic Stress Disorder

TERMINATED PHASE4

A Novel Treatment For Chronic Posttraumatic Stress Disorder (PTSD) Using Post-Reactivation Propranolol

NCT01127568

Stress Disorders, Post-Traumatic

UNKNOWN PHASE2/PHASE3

Reducing Reconsolidation of Trauma Memories With Propranolol

NCT01349439

Posttraumatic Stress Disorder

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Trauma and Stressor Related Disorders Post-traumatic Stress Disorders Adjustment Disorders Acute Stress Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Repeated measures parallel design.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Propranolol Hydrochloride

1mg / kg of propranolol hydrochloride administered as a capsule 60 minutes prior to memory reactivation

Group Type EXPERIMENTAL

Propranolol Hydrochloride

Intervention Type DRUG

1mg / kg of propranolol hydrochloride, oral capsule

Placebo

Placebo manufactured as a capsule to mimic 1mg/kg of propranolol hydrochloride administered 60 minutes prior to memory reactivation

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

1mg / kg of matched placebo, oral capsule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Propranolol Hydrochloride

1mg / kg of propranolol hydrochloride, oral capsule

Intervention Type DRUG

Placebo

1mg / kg of matched placebo, oral capsule

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Teva-propranolol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Understands and reads French
* Currently or previously worked for the Quebec City Police Department, or the 911 dispatch for Quebec City, or another police department or 911 dispatch in the province of Quebec, or for the Quebec Ministry of Public Security as a correctional service officer
* Meets criteria for a trauma-and stressor-related disorder, such as: Acute Stress Disorder, Posttraumatic Stress Disorder, Adjustment Disorder, Other Trauma- and Stressor-Related Disorder, as defined by the Diagnostic and Statistical Manual for Mental Disorders, 5th edition.
* The trauma-and stressor-related disorder must be due to a work-related event.
* A score of at least 4 (moderately ill) on the Clinical Global Impressions-Severity Scale.
* Participants who are currently taking a Selective Serotonin Reuptake Inhibitors or Selective Norepinephrine Reuptake Inhibitors (antidepressants) must accept to skip their morning dose on the days that they receive the study's intervention.

Exclusion Criteria

* Systolic blood pressure \< 100mm Hg (millimeter of mercury) at visit 0.
* Heart rate \< 55 bpm (beats per minute) at visit 0.
* Medical conditions that contraindicate propranolol administration, as determined by the treating physician.
* Previous diagnosis of a traumatic brain injury (TBI).
* Previous adverse reaction or non-compliance with a beta-blocker.
* Medications that can have an dangerous interaction with propranolol.
* Fertile women who are not using an adequate contraceptive methods.
* Pregnant women.
* Nursing women.
* The following psychiatric conditions: past or present bipolar disorder, past or present psychotic disorder, present substance abuse or dependence, actively suicidal, past or present neurological disorder, complex posttraumatic stress disorder.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No